Zusammenfassung
Die zunehmende Resistenzentwicklung bei Plasmodium falciparum ist ein weltweites Problem. Diese Studie hatte das Ziel, die in vitro Aktivität von Artemisinin, Mefloquin und Chinin bei Plasmodium falciparum in einem Gebiet mit ausgeprägter Multiresistenz, zu ermitteln. Zu diesem Zweck wurde die arzneimittelbedingte Hemmung der Schizontenreifung gemessen. Bei insgesamt 43 erfolgreich getesteten Isolaten von P. falciparum ergaben sich mittlere Hemmkonzentrationen – IC50, IC90 – für Artemisinin von 0,0081 und 0,1372 μM. Für Mefloquin ergaben sich analog die Konzentrationen 0,1260 und 3,7345 μM. Chinin zeigte eine mittlere IC50 von 0,2155 μM und eine IC90 von 2,5040 μM. Alle getesteten Medikamente zeigten einen signifikanten Wirkungsverlust im Vergleich mit Ergebnissen aus den vorangegangenen Jahren. Dies deutet auf einen weiteren Anstieg der Resistenzentwicklung bei P. falciparum hin, besonders kritisch bei Artemisinin und Chinin.
Summary
The increasing drug resistance of Plasmodium falciparum is a worldwide problem. The objective of the study was the assessment of the in vitro activity of artemisinin, mefloquine and quinine, in an area where P. falciparum is multi-drug resistant. The sensitivity tests were based on measuring the drug-dependent inhibition of schizont maturation. For the 43 successfully tested isolates the mean effective concentrations (IC50 and IC90) for artemisinin were 0.0081 and 0.1372 μM, respectively. For mefloquine the IC50 was 0.1260 μM and the IC90 was 3.7345 μM. Quinine showed an IC50 of 0.2155 μM and an IC90 of 2.5040 μM. All tested drugs showed a significant reduction in the effectiveness, compared with the results of former years. This suggests a further rise of resistance of local P. falciparum, which is alarming especially for artemisinin and quinine.
This is a preview of subscription content, log in via an institution to check access.
References
Wernsdorfer WH (1994) Epidemiology of drug resistance in Malaria. Acta Trop J 56: 143–56
Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR (2002) Epidemiology of drug resistant malaria. Lancet Infect Dis 2: 209–18
Wernsdorfer WH, Trigg PI (1988) Recent progress of malaria research: chemotherapy. In: Wernsdorfer WH, McGregor Sir IA (eds) Malaria, principles and practice of malariology. Churchill Livingstone, Edinburgh, pp 1569–674
Li GQ, Guo XB, Fu LC, Jian HX, Wang XH (1994) Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. Trans R Soc Trop Med Hyg 88[Suppl 1]: S5–6
White NJ (1996) The treament of malaria. N Engl J Med 335: 800–6
White NJ (2008) Qinghaosu (artemisinin): the price of success. Science 320: 330–4
World Health Organization (2006) Guidelines for the treatment of malaria. WHO, Geneva
Alker AP, Lim P, Sem R, Shah NK, Yi P, Bouth DM, et al (2007) Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg 76: 641–7
Denis MB, Tsuyuoka R, Poravuth Y, Narann TS, Seila S, Lim C, et al (2006) Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 11: 1360–6
Denis MB, Tsuyuoka R, Lim P, Lindegardh N, Yi P, Top SN, et al (2006) Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health 11: 1800–7
Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM (2008) Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359: 2619–20
Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends M, et al (2009) Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 4(2): e4551 [Epub 2009 Feb 23]
White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al (1999) Averting a malaria disaster. Lancet 353: 1965–7
World Health Organization (1990) In Vitro Microtest (Mark II) for the assessment of the response of Plasmodium falciparum to chloroquine, mefloquine, quinine, sulfadoxine/pyrimethamine and amodiaquine. WHO document MAP/87.2. Revision 1. WHO, Geneva
Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96: 99–113
Wernsdorfer WH, Wernsdorfer MG (1995) The evaluation of in vitro tests for the assessment of drug response in Plasmodium falciparum. Mitt Oesterr Ges Tropenmed Parasitol 17: 221–8
Preechapornkul P, Imwong M, Chotivanich K, Pongtavornpinyo W, Dondorp AM, Day NP, et al (2009) Plasmodium falciparum: Pfmdr1 amplification, mefloquine resistance, and parasite fitness. Antimicrob Agents Chemother 53: 1509–15
Brockman A, Price RN, van Vugt M, Heppner DG, Walsh D, Sookto P, et al (2000) Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg 94: 537–44
Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, et al (2000) Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356: 297–302
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hüttinger, F., Satimai, W., Wernsdorfer, G. et al. Sensitivity to artemisinin, mefloquine and quinine of Plasmodium falciparum in northwestern Thailand. Wien Klin Wochenschr 122 (Suppl 3), 52–56 (2010). https://doi.org/10.1007/s00508-010-1438-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00508-010-1438-6